Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Darren Hee

Family Medicine Tucson, AZ Medical Doctor

NPI 1902864663 CMS profile 177640

6130 N La Cholla Blvd Ste 100, Arizona Community Physicians Pc, Tucson, AZ 85741

Open in the dashboard

General payments

$1,046

72 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Darren Hee of Tucson, AZ is reported in the CMS Open Payments database as having received $1,046 across 72 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $27 1
2021 General $364 23
2020 General $220 13
2019 General $435 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Darren Hee
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Darren Hee were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Darren Hee Family Medicine median Middle half National median
2019 $435 $150 $41–$543 $163
2020 $220 $120 $32–$415 $114
2021 $364 $137 $35–$551 $132
2022 $27 $137 $37–$512 $149
2023 $0 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Pfizer Inc. $198 17 payments
  2. AbbVie, Inc. $171 9 payments
  3. GlaxoSmithKline, LLC. $111 8 payments
  4. Allergan Inc. $103 6 payments
  5. Amgen Inc. $81 5 payments
  6. Novo Nordisk Inc $71 5 payments
  7. Janssen Pharmaceuticals, Inc $54 4 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $50 3 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $29 2 payments
  10. Sanofi Pasteur Inc. $27 2 payments
  11. Other $151 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $1,046 72 payments
Products named General payments · program years 2019–2022
  1. UBRELVY $106 5 payments
  2. ELIQUIS $98 8 payments
  3. TRELEGY ELLIPTA $93 7 payments
  4. PREVNAR - 13 $64 5 payments
  5. CHANTIX $62 7 payments
  6. Ozempic $55 4 payments
  7. LINZESS $52 3 payments
  8. VRAYLAR Neuroscience $50 3 payments
  9. Repatha $48 3 payments
  10. VRAYLAR Neuroscience $45 3 payments
  11. Other $767 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 144 drugs

Part D claims

8,472

Median for Family Practice: 1,826

Drug cost

$462,842

Median for Family Practice: $120,094

Branded share of claims

19.7%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 70 $64,837
Ozempic Semaglutide Brand 53 $57,715
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 62 $53,269
Mounjaro Tirzepatide Brand 20 $31,202
Farxiga Dapagliflozin Propanediol Brand 15 $22,012
Pepcid Famotidine Brand 11 $19,709
Jardiance Empagliflozin Brand 14 $17,762
Breo Ellipta Fluticasone/Vilanterol Brand 35 $16,506
Xarelto Rivaroxaban Brand 17 $15,721
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 15 $10,059

The 10 drugs with the highest cost, of 144 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 92 billing codes

Paid by Medicare

$107,961

Of which drugs: $4,431

Medicare patients

321

Average age 77

Services billed

8,202

149 women, 172 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Chronic kidney disease 31%
Diabetes 24%
Ischemic heart disease 22%
Depression 21%
Osteoporosis 18%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 29 29 $2,343

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record